Small amounts of free DNA circulate in both healthy and diseased human plasma/serum, and increased concentrations of DNA are present in the plasma of cancer patients. Characteristics of tumor DNA have been found in genetic material extracted from the plasma of cancer patients. These features include decreased strand stability, mutations of specific oncogenes or tumor suppressor genes, gene rearrangements and amplifications, microsatellite alterations and hypermethylation of several genes. Moreover, free viral DNA such as EBV has been detected circulating in the plasma. Finally, mRNA characteristic of tumor cells has also been found in the serum of cancer patients. Malignancies studied include breast, colorectal, pancreatic cancer, head and neck, lung, kidney, breast, ovarian, bladder, nasopharyngeal, liver cancer, non-Hodgkin's lymphoma, acute B cell leukemia and melanoma. The results obtained, sometimes prior to clinical diagnosis, have opened a new research area indicating that plasma DNA might eventually be a suitable target for the development of non-invasive diagnostic, prognostic and follow-up tests for cancer. The recent demonstration of circulating tumor-derived DNA has opened up new possibilities for cancer detection and monitoring. Nasopharyngeal carcinoma (NPC) is a common cancer in South China and Southeast Asia and it is well-established that Epstein-Barr virus (EBV) has a close association with this malignancy. It has recently been shown that EBV DNA can be found in a significant proportion of plasma and serum samples from NPC patients. Our group has used real time polymerase chain reaction (PCR) techniques to establish fundamental quantitative parameters of circulating EBV DNA in NPC. Our results have shown that the levels of plasma/serum EBV DNA are higher for patients with advanced, compared with early disease. Serial sampling of plasma EBV DNA during treatment has shown a rapid decline in circulating EBV DNA level, with a median half-life of 3.8 days. We believe that this type of kinetic analysis will be useful for the evaluation of novel therapeutic modalities for NPC. Following treatment we have also shown that EBV DNA measurement allows the earlier detection of tumor recurrence than conventional methods. Finally, we have also shown that plasma/serum EBV DNA is an independent prognosticator for NPC, both with regard to early event (within the first year after treatment) and also for long-term survival. We believe that a strong case can be made for including circulating EBV DNA measurement in the routine work-up and follow-up of NPC patients. Nucleosomes are aggregates consisting of histone proteins and cellular DNA and are typical products of apoptotic cells. They are released into circulation in patients with malignant diseases and during chemo-and radiotherapy. We developed a modified version of the Cell Death Detection plus -ELISA (Roche Diagnostics) for the application in serum and established a standardized program for the preanalytic handling.
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Nuclear genetic changes drive the progression of human cancers David Sidransky Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Since the identification of clonal genetic changes in the serum of cancer patients, new directions are emerging in the development of these diagnostic approaches. Among our most promising nuclear markers is epigenetic promoter methylation. We have demonstrated the presence of promoter methylation at various target genes in a variety of head and neck and lung cancers. We are now interested in real time quantitation of methylated genomes in patients before the development of cancer. Moreover, we have also assayed the presence of HPV DNA in the serum of patients with head and neck tumors as well as cervical cancer. Finally, we have recently demonstrated the presence of homoplasmic mitochondrial mutations in human tumors. Increased copy number of these mitochondrial mutations makes them an attractive target for various diagnostic purposes. In addition to their promise as markers in draining bodily fluids, we are also investigating their use as serum markers in various tumors.
3 Viral DNA as a tumor marker in plasma and serum: application to nasopharyngeal and cervical carcinoma Wichai Pornthanakasem, Kanjana Shotelersuk, Wichai Termrunggraunglert, Narin Voravud, Somchai Niruthisard and Apiwat Mutirangura Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand To compare circulating viral DNA between cervical and nasopharyngeal cancer, (CC&NPC), incidence, type, and physical status of plasma human papillomavirus (HPV) DNA from CC were evaluated by PCR using labeled E6 degenerate primers, dot blot hybridization, and E2&E6 PCR, respectively. Among 50 HPV positive CC patients, only 6 (12%), revealed plasma HPVDNA. The HPVDNA between plasma and tumor was of the same type and integrated into the host genome. Thus the circulating HPVDNA represented tumor DNA. Interestingly, there is evidence suggesting association between plasma HPVDNA and metastases. First, three positive cases were staged IVB (PϽ0.001) in which one occurred in a previously stage IIIB patient who was then negative for circulating HPVDNA. Second, semiquantitative E6&ZP3 PCR showed plasma HPVDNA from IVB patients to be two to eight times more than three other stage IIB patients without metastases. Finally, two of the latter cases suffered recurrence with distant metastases at 7 months after complete treatment.
Whereas previous NPC studies showed that serum/plasma Epstein-Barr viral DNA was commonly detectable, resisted to DNase treatment and disappeared after initiation of radiotherapy, circulating HPVDNA was identified in one-tenth, derived from integrated HPVDNA, and associated with metastases of CC. Though both cancers are viral associated squamous cell carcinomas, the corresponding circulating viral DNA species reveal different releasing mechanism and clinical implication. In the post-genomic era, proteomics offers a new approach to studying normal and transformed cell functions, disease detection targets, and novel endpoints to evaluate chemoprevention agents and toxicity. With the era of genomic profiling challenges nearing completion, elucidation of the entire human genome sequence is going to take some time. However, the genomic information cannot give information about what is actually occurring at the protein level within a given cell type and a given time. This information is even further removed from the in vivo condition when juxtaposed to the context of a cell existing as an entity linked to the complex tissue and organ system orchestration, where cells act in concert with each other and the vasculature in a three-dimensional structure. The present repository of genomic information can only be considered a master "inventory list" about what proteins any cell could make. The National Cancer Institute's Early Detection Research Network is employing proteomics, or "protein walking," in the discovery and evaluation of biomarkers for cancer detection and for the identification of high risk subjects. Armed with the powerful use of Laser Capture Microdissection (LCM) to procure pure populations of cells directly from human tissue, the Network is facilitating the development of technologies that can overcome the problem of tissue heterogeneity. LCM, when coupled with downstream proteomics applications such as two-dimensional polyacrylamide gel electrophoresis and SELDI (surface enhanced laser desorption ionization) separation followed by mass spectrometry analysis, can greatly facilitate the characterization and identification of protein expression changes which track with the normal and diseased phenotypes. We will discuss the recent works from Network investigators to demonstrate the potential of SELDI and MALDI (matrix-assisted laser desorption ionization) to identify relevant cancer screening proteins present in tissues and body fluids. We will also discuss the complementarity of proteomics approaches to plasma-based circulating DNA assays in cancer detection and risk assessment. 7 Fetal cells in maternal blood: from pregnancy to autoimmune disease Diana W. Bianchi Department of Pediatrics, Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts 02111, USA. The isolation of fetal cells from maternal blood is currently under active investigation as a noninvasive method of prenatal genetic diagnosis. In the context of this work, we discovered that fetal cells from a prior pregnancy could persist for decades postpartum. This led to the realization that following pregnancy, a woman becomes a chimera.
The relationship between fetal cell microchimerism and maternal disease is currently being explored. During pregnancy, fetal cells in the maternal skin are associated with polymorphic eruptions of pregnancy and increased fetomaternal trafficking is detectable in cases of pre-eclampsia. After delivery, we have shown that more male DNA of presumed fetal origin is present in the blood of women with scleroderma as compared to healthy controls. Fetal cells are also detectable in autopsy tissue specimens from women with scleroderma and lupus and in surgical specimens from women with inflammatory diseases of the thyroid. Fetomaternal cell trafficking provides a potential explanation for the increased prevalence of autoimmune disorders in adult women following their childbearing years. Remarkably, some of the fetal cells are capable of further differentiation into mature organs and may thus play an additional therapeutic role.
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Fetal DNA in maternal plasma: towards non-invasive prenatal diagnosis Y.M. Dennis Lo Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, China. With the discovery of fetal DNA in maternal plasma in 1997, a new approach for non-invasive prenatal diagnosis has become possible. Through the use of quantitative molecular methods, fetal DNA has been found in maternal plasma in much greater relative concentrations than fetal nucleated cells in maternal blood. Data from multiple groups in the world have confirmed the robustness of fetal DNA detection in maternal plasma. Fetal genetic characteristics and diseases which have been detected include gender for the investigation of sex-linked diseases, rhesus D blood group status, myotonic dystrophy, achondroplasia and paternally-inherited microsatellite polymorphisms. An exciting development recently is the demonstration of apoptotic fetal cells in maternal plasma. Using these "plasma-derived fetal cells" our group has achieved the prenatal detection of fetal Down's syndrome by fluorescence in-situ hybridization analysis from maternal plasma. Apart from the qualitative detection of fetal genetic characteristics, quantitative fetal DNA abnormalities have also been detected in a number of pregnancy-associated disorders, including pre-eclampsia and preterm labor. Such findings open up new strategies for the detection and monitoring of these disorders. With future research in this emerging area, it is expected that the clinical applications of fetal DNA in maternal plasma will continue to expand rapidly.
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Circulating RNA as a tumor marker Michael S. Kopreski and Christopher D. Gocke OncoMEDx, Inc., Columbia, Maryland, USA Cancer is commonly associated with the inappropriate mRNA expression of non-mutated genes. Recently, several tumor-associated mRNA, including tyrosinase mRNA and telomerase mRNA, have been demonstrated in plasma and serum. The presence of tumor RNA in plasma and serum affords the opportunity to diagnose or stratify patients with cancer when tissue is not readily available. To exemplify the potential for pharmacogenomic and phenotypic stratification of the cancer patient, we evaluated serum for 5T4 mRNA. 5T4 is a trophoblast glycoprotein frequently overexpressed in epithelial malignancies that is a target for a cancer therapeutic in development. Serum was collected from 19 patients with advanced breast cancer (5 patients) or non-small cell lung cancer (14 patients), and from 25 normal control volunteers having amplifiable RNA. RNA extracted from the serum was RT-PCR amplified using hemi-nested, two-staged reactions, with products detected by gel electrophoresis. 5T4 mRNA was reproducibly detected in 8/19 (42%) cancer patient sera, including 2/5 breast cancer patient sera, and 6/14 lung cancer patient sera, but in only 3/25 (12%) normal control sera (pϭ0.035). The potential for circulating mRNA to select patients who might benefit from a 5T4-directed therapeutic offers one example of the utility of circulating mRNA as a tumor marker. The diagnostic and pharmacogenomic potentials of circulating RNA warrant further investigation.
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RNA detection in disseminated tumor cells A. Zippelius, R. Lutterbü se, G. Riethmü ller, K. Pantel Molekulare Onkologie, Frauenklinik, Universitätsklinikum Eppendorf, Hamburg, and Institut fü r Immunologie, LMU, Mü nchen, Germany Early systemic spread of occult tumor cells that may develop into founders of incurable distant metastasis has been identified in cancer patients by reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of mRNA species encoding for tumor-associated proteins such as cytokeratin-19 and 20, carcinoembryonic antigen or prostate-specific antigen. Nevertheless the introduction of this new staging tool into the clinical setting has been hampered by the disparate and contradictory data on the sensitivity and specificity of the RT-PCR methods. We therefore used PSA RT-PCR, as a model, to examine the influence of analytical variables such as priming and enzyme of RT reaction, temperature and time of primer annealing, primer extension and denaturation as well as the concentrations of magnesium chloride, Taq polymerase, dNTP, primers and bovine serum albumin (BSA) on the amplification process. By systematically varying these chemical and physical components, we could demonstrate a significant increase in amplification yield and in stringency of primer annealing. This may explain the wide variety of published findings on molecular staging of prostate cancer and other epithelial tumors, which currently impedes the clinical introduction of RT-PCR assays into clinical practice. Thus, methodological analyses are needed for standardization and quality assurance to achieve reproducible molecular methods. The discovery of fetal DNA in maternal plasma has opened up new possibilities for prenatal molecular diagnosis. Many groups have since shown that fetal genetic traits can be determined from fetal DNA in maternal plasma. However, it is not known whether fetal RNA is also present in maternal plasma. Using a two-stepped reverse transcriptase (RT)-PCR assay, we demonstrate the presence of fetal-derived, male-specific ZFY mRNA in plasma of pregnant women carrying male fetuses. The detection rate of plasma fetal ZFY mRNA in early (Nϭ9) and late pregnancies (Nϭ29) were 22% and 63%, respectively. In addition, of 9 filtered plasma samples collected from women carrying male fetuses in late pregnancies, positive ZFY mRNA signals were detected in 6 samples, indicating that at least a portion of fetal RNA in maternal plasma exists in cell-free from. These results suggest that maternal plasma might be a source for noninvasive detection of fetal gene expression.
12
Fetal and tumor-derived DNA in urine: a new generation of ultra-noninvasive tests A.V. Lichtenstein, H.S. Melkonyan, L.D. Tomei, S.R. Umansky Diagen Corp., 6034 Monterey Ave., Richmond, California 94805, USA From 10 11 to 10 12 cells die daily in the human body. The vast majority of these cell die by apoptosis. Apoptosis is accompanied by chromatin condensation, internucleosomal cleavage of DNA, formation of so-called apoptotic bodies, which frequently contain DNA, and cell fragmentation. Cell fragments are engulfed and finally digested by macrophages or by neighboring cells. The presence of cell-free DNA in the blood plasma suggests that a portion of DNA from the apoptotic cells escapes complete degradation. Detection in this cell free DNA of "alien" sequences, which are different from the bulk cell DNA, can be used for diagnostic purposes. However, the concentration of cell-free DNA in plasma is low, equivalent to 10 3 -10 4 cell genomes. This can seriously limit the sensitivity of plasma DNA based technology. We have recently shown that cell-free DNA derived from a fetus, tumors or transplanted cells is also detectable in urine at concentrations comparable to those observed in plasma. In many instances, availability of urine samples can represent a significant advantage for diagnostic purposes. Several important questions should be addressed in order to facilitate clinical applications of this technology: (i) Are different genome sequences equally represented in circulating cell-free DNA? (ii) How is DNA of various tissues represented in plasma and urine? (iii) Is DNA from dying cells present in plasma and urine as a free nucleoprotein, as a part of apoptotic bodies or in other form?
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Molecular medicine in the emergency room: plasma DNA in trauma T.H. Rainer Accident and Emergency Medicine Academic Unit, Room GO5, Cancer Centre, The Prince of Wales Hospital, Shatin, Hong Kong
Circulating cell-free plasma DNA is useful for the clinical diagnosis and prognosis of cancer patients, pregnant women and organ transplantation recipients, and may be liberated into plasma either as a result of apoptosis or direct injury. As bodily trauma involves considerable tissue damage, DNA may be liberated from tissues within minutes to hours after such injury. There is a positive correlation between early plasma DNA levels and injury severity, and levels are highest in those patients who develop the acute respiratory distress syndrome, multiple organ dysfunction syndrome and those who eventually die.
Plasma DNA can be measured within minutes to hours after injury using a real-time, quantitative, polymerase chain reaction assay. Using DNA and other markers entered into a Classification and Regression Tree, it is possible to derive a prediction rule for post-traumatic complications with high sensitivity, specificity and positive predictive values. These guidelines require prospective validation before they find a place as research tools.
14 On the fate of plant or other foreign genes upon the uptake in food or after intramuscular injection Urte Hohlweg, Walter Doerfler Institute of Genetics, University of Cologne, Weyertal 121, 50931 Koeln, Germany Uptake and persistence of the DNA of bacteriophage M13 and the cloned gene for the green fluorescent protein (GFP) as test genes for food-ingested DNA have previously been traced from intestinal contents, via the gut wall, Peyer patches and peripheral white blood cells to spleen and liver and via the placenta to fetuses and newborn animals. We have now chosen a natural scenario and fed soybean leaves to mice. The distribution of the plant-specific gene for the nucleus-encoded ribulose-1,5-biphosphate-carboxylase (rubiso) has been studied in the mouse organism. Plant-associated, naturally fed DNA is more stable in the intestinal tract than naked DNA. Rubiso gene-specific PCR products have also been amplified from spleen and liver DNA. There is no evidence for the expression of orally administered genes, as assessed by RT-PCR method. Moreover, mice have been continuously fed daily with GFP DNA for 8 generations and have been examined for the transgenic state. The results have been negative and argue against germline transfer of orally administered DNA. Upon intramuscular injection of GFP DNA, authentic GFP DNA fragments have been amplified by PCR up to 17 months post injection. GFP fragments can also be retrieved from the intestinal contents up to 6 h post injection. Apparently, the organism eliminates injected foreign DNA via the liver-bile-intestinal route.
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Unsolved issues in circulating nucleic acids: where do we go from here? M. Stroun Plant Biochemistry and Physiology, Faculty of Science, University of Geneva, Switzerland
Although there are a number of potential applications for plasma based DNA assays in the field of oncology and prenatal detection of genetic diseases, their clinical value will ultimately depend on the development of total or partial automation of the techniques which will allow tests on a large scale. Another possible medical implication is still the hypothetical role of circulating tumor DNA in the formation of some metastases. DNA has been shown to spontaneously pass from procaryotic cells to eucaryotic cells where it may be transcribed. The passage of DNA from eucaryotic to eucaryotic cells may also occur. Moreover, the presence of donor DNA in plasma of graft recipient opens new possibilities for post-graft follow-up. Finally the origin of the circulating DNA has not yet been solved. Lysis of circulating cancer cells or micrometastases shed by the tumor can be discarded. Two mechanisms might explain the phenomenon: apoptosis or spontaneous and active release of DNA. According to the answer, this phenomenon might bring new insights to Molecular Biology.
Circulating DNA and Cancer
Oral Presentations 16 DNA microsatellite markers with LOH in plasma from stage III melanoma patients is associated with a decreased survival D.S.B. Hoon, B. Taback, D.L. Morton, Y. Fujiwara. John Wayne Cancer Institute, Santa Monica, CA, USA Patients with stage III melanoma are at substantially increased risk for recurrence despite surgical resection of all clinically evident disease. However, relapse rates may vary widely among these patients. Tumor-associated DNA microsatellites demonstrating LOH have been detected in melanoma patients' plasma and correlate with advanced disease. In this study we evaluated whether tumor markers detected preoperatively in plasma may identify patients with a poorer prognosis.
Plasma was isolated from 27 stage III patients, preoperatively. Eight microsatellite markers in which LOH is common in melanoma were assessed: D9S157, D9S161, D10S212, D11S925, D6S264, D1S214, D1S228 and D3S1293. LOH for at least one marker was present in 17 of 27 (63%) patients' plasma. Following a median follow-up of 21 months, seven patients expired. Overall survival was significantly decreased in those patients demonstrating LOH as compared to those without LOH for any marker assessed (pϽ0.05). Furthermore, the presence of LOH on D1S228 and/or D9S157 was associated with a decreased survival in these patients.
In conclusion, these results suggest that plasma DNA markers can possess clinical utility. DNA microsatellite LOH markers in plasma may serve as a valuable surrogate molecular marker for rapid disease progression identifying patients who may/may not benefit from potential therapies. At present it has been established that low-molecular DNA (lmDNA) appears in blood plasma during some extreme conditions: malignancy, insult, infarct, and pulmonary pathology. In the present investigation we studied the influence of ionizing radiation in different doses to this marker. The experiments showed that the amount of lmDNA (180 bp) correlates directly with the irradiation dose.
The sequencing of several clones of lmDNA isolated from blood plasma of rats after irradiation at doses 8 and 100 Gy, and comparing with EMBL data, showed that there is homology between the sequence of these clones to various genomic repetitive elements. The cloned lmDNA is enriched with G/C-pairs (48% against 40% in rodent genome).
The application of the program for identification of nucleosome-positioning sequences in eukaryotic nuclear DNA showed that lmDNA fragments are able to form rather sustainable nucleosomes and had some peculiarity.
The length of cloned DNA fragments following irradiation by 100 Gy was very different in sizes in comparison with the influence of 8 Gy. It may be caused by direct influence of radiation. The differences in the composition of lmDNA after irradiation at these doses consist of the change in the levels of dinucleotides CpG and CpT. This DNA in question originates from different cell populations.
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DNA-based detection of prostate cancer in blood, urine, and ejaculates Carsten Goessl, Markus Mü ller, Rü diger Heicappell, Hans Krause, Kurt Miller Dept. of Urology, Benjamin Franklin Medical School, Free University of Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. Promoter hypermethylation of the glutathione-S-transferase P1 gene (GSTP1) characterizes more than 90% of prostate cancers but has not been found in benign prostate tissue. Therefore, methylation-specific polymerase chain reaction (MSP) targeting GSTP1 promoter sequences was applied for DNA-based detection of prostate cancer in various human body fluids.
We investigated GSTP1 promoter hypermethylation in DNA isolated from plasma, serum, nucleated blood cells, ejaculate, urine after prostate massage, and dissected prostate tissue from 33 patients with prostate cancer and 26 control patients with benign prostatic hyperplasia (BPH). Fluorescently labeled MSP products were analyzed on an automated gene sequencer.
Whereas GSTP1 promoter hypermethylation was not detectable by MSP in prostate tissue and body fluids from patients with BPH, we found it in 94% of tumors (16 of 17), 72% of plasma or serum samples (23 of 32), 50% of ejaculates (4 of 8) and 36% of urine samples (4 of 11) from patients with prostate cancer. Additionally, MSP identified circulating tumor cells in 30% (10 of 33) of prostate cancer patients.
Analysis of GSTP1 promoter hypermethylation by MSP provides a specific tool for molecular diagnosis of prostate cancer in body fluids complementing information obtained with the conventional serum tumor marker PSA. Relapse of disease is frequently encountered in nasopharyngeal carcinoma (NPC) patients. Previous retrospective analysis in our hospital by Lee et al. (1992) showed that, among NPC patients with complete tumor regression to primary radiotherapy (RT), more than half of them will later develop relapse. Chemotherapy (CT) is a common salvage modality employed to treat NPC relapse. However, conventional clinical indicators for treatment response to salvage CT are neither sensitive nor specific. In this paper, we investigated whether determining EBV DNA level in the patients' sera by TaqMan real time quantitative polymerase chain reaction (Q-PCR) could be a useful indicator to monitor the response of salvage CT. Twenty-one patients, who were recruited in a phase II clinical trial of salvage CT for relapse using a new drug combination of cisplatinum and gemcytobine were entered into this study. Longitudinally collected sera from this cohort of patients were analyzed by Q-PCR for DNA encoding Epstein-Barr virus (EBV) small RNA (EBER1) at the beginning of relapse and at an intervals of 1 ⁄2 to 3 months during/after salvage CT over a period of 1 ⁄2 to 5 years. Among them, 6/21 (29%) patients had local or loco-regional (LR) recurrence, 6/21 (29%) developed distant metastasis (DM) in single site and 9/21 (43%) had DM at 2 or multiple sites. EBER1 DNA in patients' sera was substantially elevated with relapse in 17/21 (81%) patients. On salvage CT, 17/21 (81%) patients had dramatic drop of EBER1 DNA level corresponding presumably to tumor regression in response to the drugs. The specificity of the test was demonstrated by a total serum EBER1 DNA negativity in 1/21 (5%) NPC patient who was EBV in situ hybridization negative. Detailed follow-up of the clinical course in these patients revealed an excellent correlation of EBER1 DNA level with the events of disease progression and regression. In conclusion, Q-PCR amplification of EBV gene has great potential to be developed into a routine test for monitoring salvage treatment in NPC.
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Detection of gene promoter hypermethylation in serum samples of gastric
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DNA of human papillomavirus detected by PCR in plasma of cervical cancer patients: a potential marker of residual disease Alfonso Dueñ as, Marcela Lizano, Adela L Carrillo, Joanna Wó jcik, Catalina Trejo Basic Research, Instituto Nacional de Cancerología, Department of Genetics and Environmental Toxicology, IIB, UNAM, México City Background: Cervical cancer is the leading cause of death from gynecological cancers in the world. Tumor markers, especially when sensitive and specific, are of great value in the management of cancer patients. For cervical cancer there are no known tumor markers with these characteristics that could be employed routinely. Recently, free DNA has been found in the serum or plasma of healthy individuals and cancer patients and that the amount of circulating DNA is directly related to the tumor load. Moreover, DNA sequences specific to those found in primary tumors are also detected in the plasma. This has been shown for mutated K-ras, microsatellites and IgH chain arrangements in tumors such as colon, pancreas, head and neck and lymphomas. The type of mutation found in the primary tumor is always the same as that detected in serum or plasma from these patients. The fact that HPV DNA is found in episomal or integrated forms within cervical tumors, prompted us to investigate whether these viral sequences could be detected in the plasma of cervical cancer patients and to prove its utility as a marker to predict response or tumor recurrence.
Methods: The plasma of 70 cervical cancer patients with histologically proven cervical cancer irrespective of clinical stage or histological type and whose tumors were PCR positive for the HPV were analyzed. The control groups included plasma from 24 patients with PCR documented HPV cervical infection but no invasive disease and 10 healthy women. The DNA was extracted from plasma using conventional methods and submitted to PCR amplification of ␤-globin sequences to avoid false negative results due to poor DNA quality. The ␤-globin positive cases were then analyzed for HPVL1 sequences. The association between the PCR findings in cancer and control groups was analyzed with the Fisher's exact test.
Results: We found HPV DNA sequences in the plasma of 49 out of 70 patients (70%) with cancer, while no DNA amplification was observed in control groups. There was no correlation between the presence of HPV DNA in plasma with clinical stage. Several cancer patients already treated have been followed with periodical plasma analysis and we have observed clearance of plasma HPV DNA in those achieving complete response but not in those with persistent disease. In addition, patients that achieved a complete response but relapsed, became positive for plasma HPV sequences.
Conclusions: Our data demonstrate that the detection of HPV DNA in plasma is feasible and promises to be a sensitive and specific marker of minimal residual disease. Further follow-up is needed to confirm its utility in management of cervical cancer patients. TT virus (TTV) is a recently described circular DNA virus of about 3.8 kb, which is related to the circoviridae viruses. It is commonly detected in healthy subjects and no association with any specific disease has been established. TTV was initially thought to be hepatotropic but subsequent reports have shown it to be present in several other tissues including kidney, prostate, mammary gland, brain, bone marrow and peripheral blood mononuclear cells. Plasma samples from cancer patients and healthy subjects were tested for the presence or absence of TTV by heminested PCR using primers: NG59d/NG61d/NG63d. We also developed a quantitative competitive PCR (QC-PCR) assay for TTV that permits accurate measurement of TTV DNA load. Using this assay the TTV genome load in peripheral blood mononuclear cells (PBMCs) of healthy control subjects (nϭ50) and patients with various types of cancer (nϭ148), including breast cancer, non-Hodgkin's lymphoma, colon cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and other cancers was measured. 30 amplicons were randomly selected and cloned into pGEM-T Easy Vector and subsequently sequenced to identify the TTV genotypes in PBMCs of the cancer patients. TTV DNA was detected in 69 (69%) of 100 plasma samples of cancer patients tested, and 39 (39%) of 100 plasma samples randomly selected from 1000 plasma samples from blood donors (pϽ0.05). TTV DNA was detectable in the PBMCs of 99% of the cancer patients and 86% of controls. However the median virus load was more than 100 fold higher in the cancer patients (3599 copies/per 100,000 cells) than among the control subjects (30 copies/per 100,000 cells; pϽ0.0001). There was no significant difference in TTV load among the different cancer types. Using a cut-off value of Ͼ250 copies per 100,000 PBMCs, 93.2% of cancer patients were "positive" compared to only 4% of healthy control subjects. The predominant genotype was type 2 (G2) (93.3%) amongst 30 patients, who were randomly selected from all TTV positive patients. When 88 isolates from the 30 patients were analyzed, 71.6% were found to be G2, with G1/G2 ratio of 1:4.9. This is in contrast to the findings in healthy subjects where 62% of the isolates were G1, with G1/G2 ratio of 1:0.5. Moreover, divergent TTV sequences were found in all cases; mixed infection with different genotypes of TTV was detected in 15 patients (50%). Almost all tested cancer patients have TTV infection and their TTV genome load in PBMCs is significantly higher than that in control subjects. We conclude that TTV genome load in PBMCs has the potential to be used as a biological marker for screening for cancer.
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Gross elevation of TT virus genome load in the peripheral blood mononuclear cells of cancer patients
Circulating DNA and Cancer
Poster Presentations As an initial step in studying the dynamics of tumor specific DNA in plasma after radical surgery, we extracted DNA from plasma samples taken pre-and post-operatively after three days in 25 patients with colorectal cancer. All patients were free of macroscopical and histological residues of the tumor after surgery. DNA was extracted (QIAAmp, Qiagen) from plasma and the corresponding tumors. The K-ras gene codon 12 were amplified and mutations analyzed with TGGE (temperature gradient gel electrophoresis).
16/25 (64%) of the tumor biopsies, carefully evaluated as neoplastic before sampling, harbored K-ras mutations. Of these, 9 patients (56%) had K-ras mutations in their plasma DNA. 8 of these patients still had a K-ras mutation in plasma post-operatively on day 3. These results are surprising since the half-life of nucleic acids in the circulation presumably is much shorter. However, in cancer patients this has not been studied. This may suggest that the half-life of free DNA and oligonucleotides in the circulation is prolonged in cancer patients. Hypermethylation of CpG islands of gene promoter region of a gene is an epigenetic event leading to down-regulation of gene expression. Our data suggested that distinct methylation pattern of cancer-related genes was found in bladder transitional cell carcinoma (TCC) tissues. In this study, we confirmed the feasibility of detecting gene methylation in routinely collected voided urine samples and assessed its potential diagnostic value. DNA extracted from 14 bladder TCC tumor tissue samples, the corresponding urine pellets and 11 normal urine controls were subjected to methylation specific PCR (MSP) analysis of DAPk, RAR␤, and p16 gene. Promoter methylation in tumor tissue samples was detected in DAPk (64.3%), RAR␤, (100%) and p16 (14.3%). For corresponding urine samples, methylation was also detected in DAPk (50%), RAR␤ (71.4%) and p16 (17.1%). Except for RAR␤, no aberrant methylation was detected in all normal urine samples. In this series, the sensitivity of conventional urine cytology in detection of bladder cancer was 42%. It appeared that detection of aberrant gene methylation in urine has a higher sensitivity as compared to urine cytology. Combination of different methylation markers with or without conventional urine cytology may improve the diagnostic yield and deserve further investigation. We performed microsatellite analysis of urine, serum and plasma samples of 40 bladder cancer patients. Six microsatellite markers were selected to detect shifts or LOH on chromosomes 4, 9 and 17.
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Detection of gene promotor methylation in voided urine of urinary bladder
Blood and urine specimens were collected pre-operatively by venipuncture and spontaneous micturition. DNA was extracted using a modified protocol of a commercial DNA extraction kit. The DNA was analyzed and compared to peripheral lymphocytes. For DNA-analysis we used supernatants only. Tumor specimens were obtained by transurethral resection.
Genetic alterations were detected in 26 of the 36 histologically classified bladder tumors (72%). Tumor specific alterations on chromosome 4 were confirmed in 54% of urine, 18% of serum and in 36% of plasma; on chromosome 9 in 61% of urine and both in 48% of serum and plasma; and on chromosome 17 in 45% of urine, in 59% of serum and in 55% of plasma samples. In summary, 23 of the tumors with genetic alterations could be confirmed in at least one of the body fluids and with at least one of the six primers used (88%). No relation between the detected DNA alterations on the investigated loci, the frequency of alterations respectively and the tumor staging and grading could be found.
The study indicates that the simultaneous and multiple use of tumor-specific microsatellite markers could have a clinical relevance as a non-invasive tool for diagnosis and screening of bladder cancer in patients.
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The molecular detection of prostate cancer K Patel, SA Burchill and PJ Selby Imperial Cancer Research Fund Clinical Cancer Centre, St. James' University Hospital, Leeds, U.K.
Sensitive methods for the detection of prostate cancer may be of prognostic significance and may lead to improved outcome for patients, if therapeutic intervention is successful in the treatment of low level disease. In this study the sensitivity and specificity of reverse transcriptase polymerase chain reaction (RT-PCR) and microsatellite analysis for the detection of prostate cancer were compared. RT-PCR for PSA was performed on peripheral blood (PB) from 11 patients with metastatic disease and 24 controls. Microsatellite analysis was performed on 10 patients and 4 control samples using 14 polymorphic and 2 monomorphic (BAT25 and BAT26) fluorescently labeled markers. RT-PCR for PSA was very sensitive, detecting 10 LNCaP cells spiked in 2 ml of PB, although PSA mRNA was only detected in PB from 2/11 patient samples. Furthermore, PSA mRNA was detected in normal PB (4/24 samples). Microsatellite instability and LOH were detected in 5/9 prostate tumors, but only LOH was detected in plasma from 2/9 patients.
In summary, RT-PCR for PSA is a sensitive method for the detection of prostate cancer cells, however the detection of PSA mRNA in normal PB may limit its clinical utility. Microsatellite analysis was specific for the identification of disease but sensitivity was low in patient samples.
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Circulating DNA microsatellites with LOH in early stage breast cancer patients serum is associated with increased tumor proliferation B. Taback, A.E. Giuliano, N. Hansen, D. S.B. Hoon. John Wayne Cancer Institute, Santa Monica, CA, USA LOH of DNA microsatellites is a common genetic event occurring in primary breast tumors and can be detected in blood. However, clinicopathologic correlations are limited and inconsistent which may be due to the varied patient populations assessed and differences among techniques. The purpose of this study was two-fold: 1) to demonstrate the presence of LOH in the serum from early-stage breast cancer patients (EBC), and 2) to determine whether correlations exist with known histopathologic parameters.
Preoperative serum was obtained from 56 patients (stages I and II) undergoing segmental mastectomy and sentinel lymphadenectomy, and assessed for LOH with 8 microsatellite markers: TP53, D16S421, D17S855, D17S849, D8S321, D10S197, D14S62 and D14S51. Twelve of 56 (21%) patients demonstrated LOH for at least one marker, the most frequent being D16S421 (11%). No LOH was detected in 5 patients with DCIS or those with tumors Ͻ1 cm. In all, but two cases, circulating LOH was associated with primary tumors demonstrating abnormal ploidy, increased diploid index and MIB-1 fraction.
This comprehensive study provides evidence demonstrating the presence of free tumor-related genetic markers in EBC serum. The association of these findings with tumors manifesting known pathologic features consistent with increased proliferation suggests a possible etiology for their presence.
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Downregulation of p53 and p53-abs in plasma of chemoresistant colorectal carcinoma patient after chemogene treatment consisting of Adwtp53 ؉5-FU. J. Giannios, P. Ginopoulos Department of Clinical Oncology, Peripheral Hospital of Patras "St. Andreas", Greece.
We reported a colorectal cancer patient who had developed chemoresistance due to p53 mutations which inhibited induction of PCD. The presence of mutant type p53 proteins induced the anti-p53 antibody production by human CD4ϩT cells, as detected by ELISA, immunoblotting and immunoprecipitation. Thus, high p53 antibody levels in plasma were correlated with mutant p53. Tumor DNA was extracted and purified from plasma and direct sequencing of PCR exhibited mutation in codon 249 of p53. We treated the patient with adenovirus containing wtp53cDNA and 5-FU which resulted in a significant decrease in tumor volume due to extensive tumor cell death by induction of D2 apoptotic stage, according to electron microscopy results from a biopsy specimen. Furthermore, no anti-p53 antibodies were detected in the plasma of the cancer patient with ELISA, immunoblotting and immunoprecipitation. Additionally, p53 sequence analysis by PCR in tumor DNA from plasma detected no mutations in the whole region of exon 7 due to Adwtp53 transfection. In conclusion, wtp53 function has eradicated anti-p53 antibody production and p53 mutations in the plasma of the colorectal carcinoma patient where chemogene treatment reduced the tumor volume by induction of PCD.
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Tumor markers in cancer patient blood plasma DNA A.S. Belokhvostov, A.E. Bartnovskiy, K.V. Goranin, A.A. Novik, P.V. Perestenko Russian Military Medicine Academy, St. Petersburg 194044, Russia The clonality of tumors has resulted in the mutational identity between the primary tumor and its associated metastasis, as well as any DNA that the tumor has released into the plasma. The latter phenomenon has raised the possibility that plasma DNA can be used for early cancer detection and disease monitoring.
We analyzed codon 12 mutations in the K-ras gene by enriched PCR. Mutations in exons 5, 6, 7 and 8 of the p53 tumor-suppressor gene were also assessed by SSCP analysis of PCR-amplified products.
No mutations in codon 12 of the K-ras gene were observed in tumor DNA or blood plasma in 15 lymphoma and 12 breast cancer patients. In contrast, mutations in the p53 gene were observed by SSCP analysis in blood plasma DNA samples and the corresponding tumor DNA in 8 of 12 breast cancer patients and 7 of 13 lymphoma patients. The level of mutant plasma DNA was reduced at two months after tumor removal and chemotherapy, and became undetectable in a proportion of patients at six months. In 3 cases, clinical follow up at 1 and 1.5 years revealed no evidence of residual disease. In 5 breast cancer patients, mutant p53 sequences were persistently detectable in blood plasma DNA.
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Molecular genetic markers-tumor mutant genes in plasma of cancer patients after Glutoxim treatment L.A. Kozhemyakin, A.S. Belokhvostov, A.E. Bartnovskiy. BAM Ltd., Sankt-Peterburg, Russia Tumor mutant genes can be found in blood plasma independent of tumor cell circulation in blood. Codon 12 mutations of the K-ras gene were found in plasma of pancreatic cancer patients, but not in those with breast cancer. SSCP analysis detected mutant p53 gene (exons 5, 6, 7, 8) in both cancer patient groups. Breast cancer patients were treated with standard chemotherapy after tumor removal (group 1), but a proportion of the women were additionally treated with Glutoxim, an analog of oxidized glutathione with stable disulphide bond (group 2). Glutoxim causes apoptosis in malignant cells but not in normal lymphocytes. After 3 chemotherapy courses, mutant p53 was present in 12 of 52 patients (23%) in group 1, but only in 5 of 43 (11.6%) patients in group 2. Together with the disappearance of mutant p53, a diminution of hypomethylated species of LINE mobile elements was found. Our data, therefore, demonstrated a positive effect of Glutoxim therapy. Cell-free Epstein-Barr virus (EBV) DNA has been detected in the plasma and serum of patients with Hodgkin's disease, post-transplant lymphoproliferative disease (PTLD), and acquired immunodeficiency syndrome-related lymphoma. We have recently described a strong correlation between plasma EBV DNA levels and therapeutic response in 9 patients with EBV-associated lymphoid malignancies during therapy. The present study is aimed to update our results and to determine the role of measuring plasma EBV DNA in disease monitoring. Using a real-time quantitative polymerase chain reaction assay, we studied the plasma EBV DNA levels in 35 patients with EBVassociated lymphoid malignancies (14 Hodgkin's disease, 14 natural killer/Tcell lymphoma, 4 PTLD and 3 Burkitt's-like lymphoma) at presentation and during therapy. Plasma EBV DNA was detected in 28 patients at presentation (median: 1,968 copies/ml; interquartile range: 150-17,122 copies/ml) but not in any of 35 healthy control subjects (p Ͻ0.0001). Serial measurements of plasma EBV DNA levels were performed in 21 of the patients during the course of therapy. Sixteen patients who responded to therapy demonstrated a significant reduction of plasma EBV DNA to low or undetectable levels. One patient with progressive disease during therapy demonstrated rapid increase of plasma EBV DNA levels, whereas in one patient with persistent disease the plasma EBV DNA levels remained elevated. We concluded that plasma EBV DNA is detectable in a wide range of EBV-associated lymphoid malignancies. As plasma EBV DNA levels correlate well with the therapeutic response, such analysis may be a valuable tool for monitoring clinical progress. We investigated the detectability of Epstein-Barr virus (EBV) DNA in the serum of gastric carcinoma patients in Hong Kong. Previous data have shown that approximately 10% of gastric carcinomas in Hong Kong are associated with EBV. We recruited 51 patients with gastric carcinoma from the Prince of Wales Hospital, Hong Kong and blood samples were taken from these individuals prior to surgery. Following operation, the resected tumor samples were subjected to in-situ hybridization for EBER (small EBV encoded RNA). In this cohort, 5 gastric carcinomas were EBER-positive and 32 cases were negative. In the remaining 14 cases, the tumor cells were EBER-negative but there were occasional infiltrating T lymphocytes which were EBER-positive. These 14 cases were classified as having 'background positivity'. Serum EBV DNA was detected in every one of the EBER-positive cases (median serum EBV DNA concentration: 1063 copies/mL). No serum EBV DNA was detected in any of the 32 negative cases. Cases demonstrating 'background EBER positivity' had an intermediate median serum EBV DNA concentration of 50 copies/mL. Our data thus indicate that serum EBV DNA reflects tumoral EBER status and opens up the possibility that circulating EBV DNA may be used as a tumor marker for the EBER-positive gastric carcinomas. The biological and clinical significance of serum EBV DNA detectability in the cases with 'background EBER positivity' requires further elucidation in future studies.
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Detection of circulating gastric cancer associated antigen MG7-Ag in human sera with McAb and bispecific ScFv-streptavidin fusion protein-based immuno-PCR technique Jun Ren, WenChao Liu, Le Ge, Daiming Fan and Xue Yong. Center of Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China. Background: In 1994, a novel sensitive method termed Immuno-PCR for the detection of the gastric cancer associated antigen MG7-Ag in gastric cancer cell line KATO III was reported.
Methods: The sera of patients were immobilized on wells and a specific DNA molecule, which could be amplified by PCR, was employed as a marker. The chimeric molecule used in the detecting system consists of two forms. One is made by inserting a free streptavidin which is capable of binding the biotinylated McAb and biotinylated recombinant plasmid DNA marker, respectively. The second form is that a genetically prepared fusion protein of anti-CEA ScFv-streptavidin fusion protein. The bound biotinylated DNA complex was amplified by PCR. For comparison, CEA, CA50, CA19-9 and TAG-72 were detected concurrently by radioimmunoassay and immunoradiometric assay in the same serum samples from 86 patients with gastric cancer and 83 with relevant benign diseases of stomach.
Results: Using the Immuno-PCR assay, positive results were obtained in 164 out of 198 cases with gastric cancer (82.8%). The rates of positivity in other cancers were: esophageal ca. (15/86, 17.4%), colonic ca. (40/90, 44.4%), liver ca. (0/84, 0%), ovarian ca. (1/45, 2.2%), uterine ca. (0/27, 0%) and lung ca. (4/66, 6.1%). The positive results obtained from those with benign diseases were: peptic ulcer (6/78, 7.7%), chronic gastritis (7/118, 5.9%), chronic colitis (2/60, 3.3%) and normal blood donor (2/236, 0.8%).
Conclusions: The application of Immuno-PCR in the serological diagnosis of carcinoma has the significant advantages that it can be readily applied to the clinic as well as can serve as a potential screening tool in mass survey of high-risk population for gastric cancer. To investigate the etiological association of genetic instability and mismatch repair alterations in non-small cell lung cancer (NSCLC), we investigated the frequency of the microsatellite instability (MI) of 8 polymorphic markers in 68 NSCLC patients. We also explored the association between acquisition of a replication error phenotype and mismatch repair alteration. The expression of hMLH1 mismatch repair protein was examined by immunohistochemistry in paraffin-embedded tumors from 64 patients. The promoter methylation of hMLH1 gene was examined by the PCR-based methylation assay in 68 patients. The data indicated that twenty-eight patients (41.2 %) evidenced instability in multiple tested microsatellite markers ranging from 3 to 7 and were defined as MI-positive patients. Twenty MI-positive patients (76.9%) had no expression of hMLH1 protein (P ϭ 0.03) and the negative expression of hMLH protein may be associated with hypermethylation of the hMLH1 promoter. Our data suggest that MI plays a significant role in NSCLC tumorigenesis in Taiwan. In addition, MI may be associated with the altered expression of hMLH1 mismatch repair protein, which may result from promoter hypermethylation of the hMLH1 gene.
Circulating Fetal DNA and Fetal Cells
Oral Presentations An increased fetal DNA concentration in maternal plasma was observed in pathological placental conditions associated with hypertension and preeclampsia. To confirm these data, real-time quantitative PCR on the SRY gene was performed in physiological and pathological male-bearing pregnancies. In 44 physiological pregnancies, fetal DNA concentration was 22.7, 20.8, 36.1 and 74.2 genome-equivalents (g.e.)/mL during the first, second and third trimesters and at term, respectively. In seven preeclamptic women fetal DNA concentration ranged from 59.3 to 615.2 g.e./mL (mean value 325.1). In five women with preeclampsia and intra-uterine growth retardation (IUGR) fetal DNA ranged from 96.5 to 512.3 g.e./mL (mean value 203.2). In four women with IUGR and hypertension fetal DNA ranged from 34 to 473.5 g.e./mL (mean value 198.1). In three patients with IUGR fetal DNA ranged from 168.6 to 519.7 g.e./mL (mean value 332.1). In one patient with IUGR and HELLP syndrome fetal DNA concentration was 394.1 g.e./mL. Four women who developed preeclampsia some weeks later showed fetal DNA levels within the physiological range. These data suggest that increased fetal DNA concentrations might represent a valuable marker of placental abnormalities, and suggest that this elevation may precede clinical manifestation of preeclampsia by only a few weeks.
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Both maternal and fetal cell free DNA in plasma fluctuate Sinuhe Hahn, Xiao Yan Zhong, Martin R. Bü rk, Carolyn Troeger, Anjeung Kang and Wolfgang Holzgreve Dept. OB/ GYN, University of Basel, Schanzenstrasse 46, CH 4031, Basel, Switzerland. Real time quantitative analyses of extracellular fetal and maternal DNA in maternal plasma have indicated that that the levels of these molecular analytes are elevated in pregnancies with preeclampsia. In addition elevations in free fetal DNA levels have been noted in pregnancies affected by preterm labor and in those with aneuploid fetuses.
The possible diagnostic use of these new observations depends on the stability of the levels of these analytes in the maternal circulation. For this purpose we have examined the levels of total free DNA in blood samples taken longitudinally from normal healthy donors as well as the quantities of free fetal and free maternal DNA in samples obtained from normal pregnancies.
Our data show that in normal non-pregnant donors the total quantity of free DNA varied by an average of 13.5 fold. The amount of free maternal DNA similarly fluctuated by an average of 21.5 fold, whereas the mean variation in the amount of free fetal DNA was determined to be 2.2 fold. The variation between these two parameters was found to occur independently of each other. Our data imply that care should be taken when considering diagnostic applications of this technology.
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Use of Annexin V antibody to identify apoptotic cells during pregnancy A. Kolialexi 1 , G. Th. Tsangaris 2 , A. Mavrou 1 , A. Antsaklis 3 , F. Tzortzatou 2 , V. Touliatou 1 and C. Metaxotou 1 1 Medical Genetics, 2 Oncology Unit -1 st Department of Pediatrics, 3 1 st Department of Obstetrics & Gynecology, Athens University Medical School, Athens, Greece In a previous study we demonstrated that apoptosis increased according to gestational age, accounting partly for the presence of free fetal DNA in maternal plasma and serum. Using simultaneous TUNEL assay and FISH analysis we identified the fetal origin of part of the apoptotic cell population but very few TUNELϩ cells showed hybridization signals since they were in a late apoptosis stage and nuclei were distorted.
In the present study apoptotic cell population was identified immunocytochemically using Annexin V, a marker of cells in early stage of apoptosis. Apoptosis was determined in mononuclear cells isolated from the peripheral blood of 20 pregnant women in the 16 th -19 th week of pregnancy. The mean apoptosis rates using Annexin V was 6.8 Ϯ 0.5% (range: 4.2-8.1%) FISH using X and Y chromosome specific probes was applied in 11 cases known to be carrying male fetuses. The proportion of apoptotic cells showing X/Y signals was 7.8% (range: 5-12%) while 75% of Annexin V ϩ cells showed hybridization signals.
Although our results are still preliminary, it seems that use of Annexin V antibody to detect apoptotic cell population improves FISH analysis and allows a more accurate determination of the proportion of fetal cells among the apoptotic cell population. More frequent and quantitatively greater fetal microchimerism (FM) was found in whole blood from parous women with scleroderma (SSc) compared to healthy controls. However, it is not known whether this quantitative difference is due to circulating cells of fetal origin or free fetal DNA in the peripheral circulation reflecting damage in disease-affected tissues.
To distinguish the origin of FM, we tested PBMCs and plasma from healthy women and women with SSc who had previously given birth to a son, by a sensitive real time quantitative PCR assay for the Y-chromosome specific sequence DYS14. Preliminary results indicate FM was higher in PBMCs from patients compared to controls with a range of 0.00 -21.15 and 0.00 -1.32 copies of fetal DNA/ million maternal DNA copies respectively. PBMCs results were significantly higher in patients compared to controls (pϭ0.04, two-sided Student's t-test). In contrast, there was no quantitative difference of FM between patients and controls in plasma (pϭ0.84, two-sided Student's t-test).
In conclusion, the quantitative difference of FM observed in whole blood from women with SSc compared to controls appears to be cellular in origin. Further studies are necessary to determine which cell populations are specifically involved.
Circulating Fetal DNA and Fetal cells
Poster Presentations We have previously shown that multiple paternally inherited fetal loci, such as the RhD and SRY genes, can be determined in a non-invasive manner using free fetal DNA in the maternal circulation by multiplex PCR. In order to optimise this procedure for diagnostic applications we have developed an efficacious multiplex Taqman assay.
By the use of real time PCR we have also observed that the levels of free fetal DNA are elevated in pregnancies affected by preeclampsia, similar to what we have observed for fetal cell traffic. We, however, also observed that the levels of free maternal DNA were similarly elevated in preeclamptic pregnancies and that the increments in both free DNA species correlated to each other and to the degree of disease severity. Our data, therefore, indicate that in preeclampsia both the fetal and maternal compartments are affected in a co-ordinated manner.
Since elevated numbers of fetal cells have been noted in pregnancies with certain aneuploid fetuses, we have quantified free fetal DNA levels in such pregnancies. Our data showed that free fetal DNA levels are elevated in pregnancies with trisomy 21 fetuses, but not in those with trisomy 18 fetuses, remarkably paralleling previous reports on fetal cell numbers. Median cell-free male fetal DNA in maternal plasma of preeclamptic women is increased fivefold compared with control pregnant women (Lo, 1999) . We determined whether the development of HELLP-syndrome (hemolysis, elevated liver enzymes and low platelet count) in preeclamptic women is accompanied by an even further increase in cell-free DNA. Three groups of pregnant women, all carrying male fetuses were matched for gestational and maternal age: pregnant normotensive women (nϭ10), preeclampsia without (nϭ7) and with HELLP-syndrome (nϭ10). Real-time quantitative PCR was used to quantify male fetal DNA (the SRY gene on the Y chromosome) and total DNA (fetal and maternal; the albumin gene) in plasma. The median circulating fetal DNA increased significantly: 88 cell-equivalents(CE)/ml in normotensive women, 298 CE/ml in preeclamptic women and 3104 CE/ml in concurrent HELLP-syndrome. The median fractional concentration of fetal DNA (SRY/albumin) in the circulation was similar for normotensive (8.5%) and preeclamptic women (7.6%), but decreased significantly for preeclamptic women with HELLP-syndrome (1.4 %), as total albumin DNA increased even more, probably due to general tissue destruction in HELLP-syndrome. These findings may prove useful i) to obtain insight in the pathophysiological conditions causing HELLP-syndrome and ii) to predict the development of this severe variant of preeclampsia.
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Quantitation of fetal DNA in maternal serum in normal and aneuploid pregnancies Osamu Samura, Yoko Ohashi, Norio Miharu, Hiroshi Honda, and Koso Ohama Department of Obstetrics and Gynecology, Hiroshima University School of Medicine, Japan
We investigated whether the amount of circulating cell-free fetal DNA in maternal serum is influenced by fetal karyotype, using real-time quantitative polymerase chain reaction (PCR) assay. Serum samples were obtained from pregnant women at gestational ages ranging from 15 to 17 weeks, prior to their undergoing amniocentesis. In total, we examined 70 samples consisting of 55 cases of pregnancy with 46,XY, 5 cases with 47,XY,ϩ21, 3 cases with 47,XY,ϩ18, a single case with 46,XY,dup(1) and 2 cases with twins of 46,XY, and 4 cases with 46,XX which were used as negative controls. We measured the concentration of the SRY sequence as a molecular marker for fetal DNA. The SRY sequence was detectable and measurable when the fetuses were male except for one case with 47,XY,ϩ18. This case showed fetal growth retardation and bradycardia. No amplification signals of the SRY sequence were detected when the fetuses were female. The mean concentration of fetal DNA in maternal serum was 31.5 copies/ml in the pregnancy with 46,XY, 23.5 copies/ml in the pregnancies with 47,XY,ϩ21 and 21.5 copies/ml in the pregnancies with 46,XY,ϩ18. There were no significant differences in the concentration of fetal DNA between pregnancies with fetuses of normal karyotype and those with fetuses of abnormal karyotype.
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Fetal gender diagnosis with fetal DNA in maternal serum at the early gestational periods Hiroshi Honda, Norio Miharu, Yoko Ohashi, Osamu Samura, Koso Ohama Department of Obstetrics and Gynecology, Hiroshima University School of Medicine, Japan Objectives: To assess the possibility of fetal gender diagnosis with conventional PCR using maternal serum obtained at the early gestational periods and to quantify the fractional concentration of fetal DNA in them.
Materials and Methods: Blood samples were obtained from 81 pregnant women at 5 to 10 weeks of gestation. DNA was extracted with QIAamp blood kit. For fetal gender diagnosis, 40 cycles of PCR detecting the Y-specific DYS14 gene were performed. To quantify the fractional concentration of fetal DNA in maternal serum, 50 cycles of real-time quantitative PCR of SRY and beta-globin genes were carried out, respectively.
Results: We found 40 pregnant women carrying a male fetus. The DYS14 sequence was detected in each serum sample collected from 38 of the male-bearing pregnant women (95%). The concentration of SRY gene ranged from 1.7 to 148.7 copies per ml (mean: 37.2), and then the fractional concentration of fetal DNA in maternal serum ranged from 0.046 to 4.18% (mean: 1.01).
Conclusions: It is possible to diagnose the fetal gender with conventional PCR using maternal serum obtained at the early gestational periods. We also showed that the fractional concentration of fetal DNA in maternal serum obtained at the early gestational periods was about 1% on average.
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Detection of fetal NRBCs in maternal blood of pregnant carriers of ␤؊thalassemia using anti ␥ and anti monoclonal antibodies A. Mavrou 1 , A. Kolalexi 1 , A. Antsaklis 2 , X. Krikos 3 , A. Koratzis 4 , and C. Metaxotou 1 . 1 Medical Genetics, 2 1 st Department of Obstetrics and Gynecology, 3 
st Department of Pediatrics, Athens University School of Medicine, 4 Department of Obstetrics and Gynecology, University of Patras School of Medicine, Greece
Objective: Fetal nucleated red blood cells (NRBC) in maternal circulation constitute a potential source for non-invasive prenatal diagnosis. It was shown, however, that female carriers of ␤Ϫthalassemia may themselves produce erythroblasts during pregnancy, making it difficult to distinguish between fetal and maternal NRBCs. Use of Ab against embryonic hemoglobin may increase specificity for fetal NRBC detection.
Materials and Methods: MACs was used for fetal cell enrichment from peripheral blood of 50 pregnant female carriers of ␤Ϫthalassemia and NRBCs were identified by immunophenotyping using anti ␥ or anti monoclonal antibodies. FISH analysis was performed in 22 cases known to be carrying male fetuses with X and Y chromosome probes.
Results: Anti-␥ or anti-ϩ NRBCs were identified in all samples. The mean number with anti ␥ was 51 (range 14 -158) in the 1 st trimester and 52 (range 22-153) in the 2 nd trimester. Using anti 12 (range 3-23) NRBCs were identified in the 1 st trimester and 4.5 (range 3-10) in the 2 nd trimester. FISH results were concordant with the sex of the fetus. All anti ϩ cells were XY, while anti ␥ identified both XX and XY NRBCs.
Conclusion: Anti monoclonal antibody shows increased specificity for fetal NRBCs and should be preferentially used when the mother may herself produce NRBC during pregnancy. The development of a real-time quantitative TaqMan PCR assay permits the high quality analysis of DNA or RNA. With the TaqMan PCR, Lo. et al. (1998) were successful in measuring the concentration of fetal DNA in maternal plasma and serum.
Using ABI PRISM 7700 System (PE Applied Biosystems), we tried to detect the target DNA sequence of SRY and beta actin locus in the PEP (primer extension preamplification) products from a single cell. Single NRBCs (nucleated red blood cells) were retrieved from cord blood smear of male fetus using a micromanipulator. The detection rates of beta actin and SRY locus were 55% and 35%, respectively. Quantitative results of PEP products from single NRBCs were 0.5-59.5 (mϭ4.8) copies in beta actin and 2.4-278.4 (mϭ17.8) copies in SRY locus. Our quantitative data show the concentration of a single locus DNA amplified by PEP from a single NRBC.
The advantages of PEP-TaqMan PCR system are high specificity and sensitivity. This system seems a powerful tool for fetal DNA diagnosis from maternal blood.
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Elimination mechanism of fetal nucleated erythrocytes in maternal circulation Tetsuro Kondo, Akihiko Sekizawa, Akira Watanabe, Hiroshi Saito, Takashi Okai Department of Obstetrics and Gynecology, Showa University School of Medicine, Japan Objectives: Fetal cells and DNA are known to circulate in maternal blood. It is uncertain how fetal cells were transferred into maternal circulation, despite the fact that the maternal immune system could be induced to eliminate the fetal cells when fetal cells cross into maternal circulation. It is reported that fetal nucleated erythrocytes (NRBC) in maternal blood obtained at therapeutic termination showed apoptotic changes. The aim of the study is to investigate the elimination mechanisms of fetal cells circulating in maternal blood.
Methods: Informed consent was obtained from the mother and umbilical cord venous blood was obtained at normal delivery. Blood (150 l) was incubated with 6 ml PB-MAX karyo-typing medium under different concentrations of oxygen for 24 hours. Cells were washed with PBS and centrifuged. The residues were smeared and the cell number was counted by Giemsa staining. Apoptosis of the cells were determined by TUNEL method.
Results: When the cells were exposed at 20% oxygen, the cell number was significantly lower than that exposed at 1% oxygen (p Ͻ0.05). Apoptotic cell number increased according to the duration of incubation.
Conclusions: Apoptosis in fetal NRBCs might be accelerated by high concentration of oxygen in maternal blood. Objective: Umbilical cord blood is a source of hematopoietic stem cells for transplantation. Although the first clinical applications were encouraging, concern has been raised about contamination of umbilical blood by maternal cells, which might constitute a theoretical risk of graft versus host disease. The aim of this study was to assess the frequency of maternal DNA contamination in umbilical cord plasma using fluorescent PCR amplification of highly polymorphic short tandem repeat DNA markers.
